Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson’s disease

Fluids and Barriers of the CNS

Wei Zheng¹  Christopher A Bates¹ 

[1] School of Health Sciences, Purdue University, 550 Stadium Mall Drive, HAMP 1173, West Lafayette, IN 47907, USA

关键词: Neurons;    Blood-cerebrospinal fluid barrier;    Blood–brain barrier;    α-Synuclein;    Parkinson’s disease;   

Others  :  1098263
DOI  :  10.1186/2045-8118-11-17

 received in 2014-04-19, accepted in 2014-07-21,  发布年份 2014

【 摘 要 】

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the accumulation of α-Synuclein (a-Syn) into Lewy body inclusions and the loss of dopaminergic neurons in the substantia nigra (SN). Accumulation of a-Syn can induce a progressive, cyclical pathology that results in the transmission of toxic, aggregated a-Syn species to healthy neurons, leading to further neurodegeneration such as occurs in PD. The blood–brain barrier (BBB) and blood-cerebrospinal fluid (CSF) barriers (BCSFB) are responsible for regulating the access of nutrients and other molecules to the brain, but very little is known about their regulatory roles in maintaining the homeostasis of a-Syn in the CSF and brain parenchyma. This review analyzes the current literature reports on the transport of a-Syn by various brain cell types with a particular focus on the potential transport mechanisms of a-Syn at the BBB and BCSFB. The indication of altered a-Syn transport by brain barriers in PD pathoetiology and the perspectives in this research area are also discussed.

【 授权许可】

   
2014 Bates and Zheng; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kamel F: Paths from pesticides to Parkinson’s. Science 2013, 341:722-723.
• [2]Auluck P, Caraveo G, Lindquist S: α-synuclein: membrane interactions and toxicity in Parkinson's disease. Ann Rev Cell Dev Biol 2013, 26:211-233.
• [3]Braak H, Bohl JR, Müller CM, Rüb U, de Vos RAI, Del Tredici K: Stanley Fahn lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Movement Dis 2006, 21:2042-2051.
• [4]Duda JE, Lee VMY, Trojanowski JQ: Neuropathy of synuclein aggregates: new insights into mechanisms of neurodegenerative diseases. J Neurosci Res 2000, 61:121-127.
• [5]Murphy D, Rueter SM, Trojanowski JQ, Lee VMY: Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000, 20:3214-3220.
• [6]Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ: A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002, 22:3090-3099.
• [7]Clayton DF, George JM: Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999, 58:120-129.
• [8]Ellis CE, Murphy EJ, Mitchell DC, Golovko MY, Scaglia F, Barceló-Coblijn GC, Nussbaum RL: Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking α-synuclein. Mol Cell Bio 2005, 25:10190-10201.
• [9]Winklhofer KF, Haass C: Mitochondrial dysfunction in Parkinson’s disease. Biochem Biophys Acta 1802, 2010:29-44.
• [10]Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE: α-synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 2013, 73:155-169.
• [11]Bodner CR, Maltsev AS, Dobson CM, Bax A: Differential phospholipid binding of α-synuclein variants implicated in Parkinson’s disease revealed by solution NMR spectroscopy. Biogeosciences 2010, 49:862-871.
• [12]Kirik D, Rosenblad C, Burger C, Lundberg C, Johanson TE, Muzyczka N, Mandel RJ, Björklund A: Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J Neurosci 2002, 22:2780-2791.
• [13]Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjòrklund A: Nigrostriatal a-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson’s disease. PNAS 2003, 100:2884-2889.
• [14]Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, Grant LM, Ciucci MR, MacKeigan JP, Sortwell CE: Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS ONE 2013, 8:1-15.
• [15]Lee H, Patel S, Lee S: Intravesicular localization and exocytosis of α-synuclein and its aggregates. J Neurosci 2005, 25:6016-6024.
• [16]Lee H, Khoshaghideh F, Patel S, Lee S: Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004, 24:1888-1896.
• [17]Lee H, Cho E, Lee KW, Kim J, Cho S, Lee S: Autophagic failure promotes the exocytosis and intracellular transfer of α-synuclein. Exp Mol Med 2013, 45:1-9.
• [18]Brown PD, Davies SL, Speake T, Millar ID: Molecular mechanisms of cerebrospinal fluid production. Neurosci 2004, 129:957-970.
• [19]Smith DE, Johanson CE, Keep RF: Peptide and peptide analog transport systems at the blood-CSF barrier. Adv Drug Del Rev 2004, 56:1765-1791.
• [20]McCaffrey G, Davis TP: Physiology and pathophysiology of the blood–brain barrier p-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery. J Investig Med 2012, 60:1131-1140.
• [21]Sobue K, Yamamoto N, Yoneda K, Hodgson ME, Yamashiro K, Tsuruoka N, Tsuda T, Katsuya H, Miura Y, Asai K, Kato T: Induction of blood–brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res 1999, 35:155-164.
• [22]Abbott NJ, Rönnbäck L, Hansson E: Astrocyte-endothelial interactions at the blood–brain barrier. Nature Rev 2006, 7:41-53.
• [23]Kim KS: Mechanisms of microbial traversal of the blood–brain barrier. Nature Rev 2008, 6:625-626.
• [24]Bernacki J, Dobrowolska A, Nierwińska K, Małecki A: Physiology and pharmacological role of the blood–brain barrier. Pharmacol Rep 2008, 2008(60):600-622.
• [25]Zheng W, Aschner M, Ghersi-Egea J: Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol 2003, 192:1-11.
• [26]Johanson CE, Duncan JA, Stopa EG, Baird A: Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharma Res 2005, 22:1011-1037.
• [27]Spector R, Johanson CE: Sustained choroid plexus function in human elderly and Alzheimer’s disease patients. Fluids Barriers CNS 2013, 10:28.
• [28]Desplats P, Lee H, Bae E, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee S: Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. PNAS 2009, 106:13010-13015.
• [29]Angot E, Steiner JA, Lema Tomé CM, Ekström P, Mattson B, Björklund A, Brundin P: Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS ONE 2012, 7:1-11.
• [30]Lee H, Suk J, Bae E, Lee J, Paik SR, Lee S: Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int’l J Biochem Cell Bio 2008, 40:1835-1849.
• [31]Freeman D, Cedilos R, Choyke S, Lukic Z, McGuire K, Marvin S, Burrage AM, Sudholt S, Rana A, O’Connor C, Wiethoff CM, Campbell EM: Alpha-synuclein induces lysosomal rupture and cathespin-dependent reactive oxidative species following endocytosis. PLoS ONE 2013, 8:e62143.
• [32]Büchel F, Saliger S, Dräger A, Hoffman S, Wrzodek C, Zell A, Kahle PJ: Parkinson’s disease: dopaminergic neuronal model is consistent with experimental finding of increased extracellular transport of α-synuclein. BMC Neurosci 2013, 14:1-12.
• [33]Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H: NACP/α-synuclein-positive filamentous inclusions in astrocytes, and oligodendrocytes of Parkinson’s disease brains. Acta Neuropathol 2000, 99:14-20.
• [34]Braak H, Sastre M, Del Tredici K: Development of α-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson’s disease. Acta Neuropathol 2007, 114:231-241.
• [35]Lee H, Kim C, Lee S: Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection. Oxid Med Cell Longev 2010, 3:283-287.
• [36]Lee H, Suk J, Patrick C, Bae E, Cho J, Rho S, Hwang D, Masliah E, Lee S: Direct transfer of a-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010, 285:2962-9272.
• [37]Kim JN, Kim MK, Cho KS, Choi CS, Park SH, Yang S, Joo SH, Park JH, Bahn G, Shin CY, Lee H, Han S, Kwon KJ: Valproic acid regulates α-synuclein expression through JNK pathway in rat primary astrocytes. Biomol Ther 2013, 21:222-228.
• [38]Tamo W, Imaizumi T, Tanji K, Yoshi H, Mori F, Yoshimoto M, Takahashi H, Fukuda I, Wakabayashi K, Satoh K: Expression of α-synuclein, the precursor of non-amyloid β component of Alzheimer’s disease amyloid, in human cerebral blood vessels. Neurosci Lett 2002, 326:5-8.
• [39]Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, Sixel-Döring F, Hakimi M, VonSattel J, Nussbaum R, Trenkwalder C, Schlossmacher MG: α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm 2012, 119:739-746.
• [40]Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, Mann DMA, Allsop D: A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease. Sci Rep 2013, 3:2540.
• [41]Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J: DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010, 133:713-726.
• [42]Mollenhauer B, Trautmann E, Taylor P, Manniger P, Sixel-Döring F, Ebentheuer J, Trenkwalder C, Schlossmacher MG: Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. J Neurosci Lett 2013, 532:44-48.
• [43]Walker SJ, Grant KA: Peripheral blood α-synuclein mRNA levels are elevated in cynomolgus monkeys that chronically self-administer ethanol. Alcohol 2006, 38:1-4.
• [44]Fauvet B, Kamdem MM, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, Aebischer P, El-Agnaf OM, Masliah E, Lashuel HA: Alpha-Synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J Biol Chem 2012, 287:15345-15364.
• [45]Grathwohl SA, Steiner JA, Britschgi M, Brundin P: Mind the gut: secretion of α-synuclein by enteric neurons. J Neurochem 2013, 125:487-490.
• [46]Bates CA, Zheng G, Fu X, Zheng W: Expression and aggregation of α-synuclein in the blood-CSF barrier: Initial evidence for the influence of cellular manganese and copper status [abstract]. Toxicologist 2013, 132:1862.
• [47]Zheng W, Zhao Q: Establishment and characterization of an immortalized Z310 choroidal epithelial cell line from murine choroid plexus. Brain Res 2002, 958:371-380.
• [48]McMahon HT, Boucrot E: Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nature Rev Mol Biol 2011, 12:517-533.
• [49]Bates CA, Fu X, Ysselstein D, Rochet J, Zheng W: Transport of α-synuclein at the blood-cerebrospinal fluid barrier and effects of heavy metal toxicities: potential role in Parkinson’s disease pathoetiology [abstract]. Toxicologist 2014, 138:1349.
• [50]André C, Truong TT, Robert JF, Guillaume YC: Effect of metals on herbicides-α-synuclein association: a possible factor in neurodegenerative disease studied by capillary electrophoresis. Electrophoresis 2005, 26:3256-3264.
• [51]Santner A, Uversky VN: Metalloproteomics and metal toxicology of α-synuclein. Metallomics 2010, 2:378-392.
• [52]Cookson MR, Hardy J, Lewis PA: Genetic neuropathology of Parkinson’s disease. Int J Clin Exp Pathol 2008, 1:217-231.
• [53]Covy JP, Giasson BI: α-synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson’s disease. Neurotox 2011, 32:622-629.
• [54]Yue Z, Yang XW: Dangerous duet: LRRK2 and α-synuclein jam at CMA. Nat Neurosci 2013, 16:375-377.
• [55]Kisos H, Puka K, Ben-Hur T, Richter-Landsberg C, Sharon R: Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies. PLoS ONE 2012, 7:e46817.
• [56]Lee H, Suk J, Bae E, Lee S: Clearance and deposition of extracellular α-synuclein aggregates in microglia. Biochem Biophys Res Comm 2008, 372:423-428.